TABLE 4.
Predicted Effects for Various Screening Strategies per 1,000 Men
| Screening strategy | Prostate cancer deaths averted* | Life-years gained* | QALYs gained* (95% confidence interval) | Number of biopsies |
| No screening | (reference) | (reference) | (reference) | 0.0 |
| Strategy 1 | 4.7 | 57.8 | 46.9 (45.9–47.9) | 151.0 |
| Strategy 2 | 5.6 | 69.0 | 57.0 (55.9–58.0) | 151.0 |
| Strategy 3 | 5.7 | 69.8 | 57.7 (56.6–58.8) | 151.0 |
| Strategy 4 | 5.6 | 68.6 | 56.9 (55.8–58.0) | 151.0 |
| Strategy 5 | 5.6 | 68.1 | 56.4 (55.4–57.5) | 151.0 |
| Strategy 6 | 5.6 | 68.6 | 57.3 (56.3–58.4) | 128.3 |
| Strategy 7 | 5.8 | 70.5 | 59.3 (58.2–60.3) | 127.3 |
| Strategy 8 | 5.7 | 69.4 | 60.4 (59.4–61.4) | 83.9 |
| Strategy 9 | 5.6 | 68.3 | 59.4 (58.4–60.4) | 83.2 |
*
Compared with no screening.
Screening strategies are defined in Table 1. Effects are shown without discount.